Clinical trials: Light Sensitivity
Renal Fanconi Syndrome, Photophobia
Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Cystinosis disease from the blood
- Conditions
- Renal Fanconi Syndrome, Photophobia, Hypophosphatemia
- Trial name
- BioCystinosis (NCT02837523)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Migraine
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.
- Trial name
- NCT03934086
- Testing
- rimegepant
- Sponsor
- Pfizer
Dry Eye, Contact Lens Acute Red Eye
Performance and Tolerability of the Medical Device LACRIACT
The goal of this study is testing LACRIACT® eye drops, a medical device, to see how well it works and if people can use it safely.
- Conditions
- Dry Eye, Contact Lens Acute Red Eye, Photophobia, Discomfort
- Trial name
- NCT06159569
- Testing
- LACRIACT
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Laboratórios Baldacci S.A
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Asthma
Validation of Structured Light Plethysmography: Asthma
Validation of Structured Light Plethysmography (SLP) in patients with asthma, in patients with acute asthma; an observational study in healthy participants and during patients' clinical investigation of broncho-reversibility in…
- Trial name
- SLPBD (NCT02543333)
- Where
- 2 sites in United Kingdom
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Pneumacare Ltd
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer
Migraine
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Migraine is a very common, neurological disorder, characterized by recurrent episodes of headache, potential progression to more frequent and severe attack patterns, and associated symptoms.
- Trial name
- COMIG (NCT04114630)
- Testing
- erenumab 70mg/mL
- Where
- 27 sites in Spain
- Sponsor
- Novartis Pharmaceuticals
Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
- Trial name
- NCT05156398
- Testing
- Rimegepant
- Where
- 93 sites in United States, Canada and 5 more
- Volunteers
- 640 people
- Sponsor
- Pfizer
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Hepatitis C Virus
TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light
The purpose of the study is to evaluate the potential effect of TMC435 on the sensitivity of the skin towards exposure to sunlight.
- Trial name
- NCT01124799
- Testing
- TMC435, Ciprofloxacin
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Migraine, Photophobia
An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack
The purpose of the study is to show the efficacy of a single dose of PRO-513 for treating subjects suffering moderate pain form a migraine attack, with or without aura.
- Conditions
- Migraine, Photophobia, Phonophobia
- Trial name
- NCT00330850
- Testing
- PRO-513
- Where
- 16 sites in United States
- Volunteers
- 650 people
- Sponsor
- ProEthic Pharmaceuticals
Migraine
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
- Trial name
- NCT04804033
- Testing
- BHV-3500 (zavegepant)
- Where
- 116 sites in United States
- Volunteers
- 1,753 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application
The main goal of this present study is evaluate the decreasing of necessity of topic corticoids usage to control outbreaks of light to moderate atopic dermatitis by using the correct emollients.
- Trial name
- NCT01063218
- Testing
- Emollient - Cetaphil Advanced
- Where
- 2 sites in Brazil
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Galderma Brasil Ltda.
Dermatitis, Atopic
Treatment of Atopic Dermatitis by a Full-Body Blue Light Device
Multicentric, placebo-controlled, double-blinded, three-armed, prospective, randomized controlled trial.150 patients diagnosed with atopic dermatitis will be randomized to arm 1 (irradiation for 30min at 415nm wavelength), arm 2…
- Trial name
- AD-Blue (NCT03085303)
- Testing
- Full Body Blue Light Device
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 87 people
- Sponsor
- Philips Electronics Nederland BV
Migraine Headaches
Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
This is a Phase 1/ Phase 2, 12-week, multi-center, randomized, double-blind, cross-over, placebo-controlled study to evaluate the efficacy and safety of ELS-M11 compared to placebo in 50 male and female subjects, aged 18 to 65…
- Trial name
- NCT02057315
- Testing
- ELS-M11
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Achelios Therapeutics
Acne Vulgaris
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a photoallergic reaction when exposed to UV and VIS light on skin of healthy volunteers.
- Trial name
- NCT01119651
- Testing
- Tazarotene (Patch application in Challenge Phase)
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Migraine, Episodic Migraine
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
- Conditions
- Migraine, Episodic Migraine, Phonophobia, Photophobia
- Trial name
- NCT05207865
- Testing
- Rimegepant
- Where
- 19 sites in United States
- Volunteers
- 441 people
- Sponsor
- Pfizer
Photosensitivity
The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer
This is a 6-visit, single-center, non-dispensing, randomized, single-masked, 5×5 crossover study. Subjects will participate in 6 scheduled over the duration of approximately 10.5 months.
- Trial name
- NCT04811079
- Testing
- 419 nm Spectacle Filter, 437 nm Spectacle Filter, 456 nm Spectacle Filter
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Migraine
Acute Treatment Trial in Adult Subjects With Migraines
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
- Trial name
- NCT03872453
- Testing
- Zavegepant, Intranasal Aptar Pharma Unit Dose System
- Where
- 82 sites in United States
- Volunteers
- 2,154 people
- Sponsor
- Pfizer